TCM
AGIO icon

Triumph Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Triumph Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71K Hold
100
– – ﹤0.01% 1448
2026
Q1 		$3.38K Hold
100
– – ﹤0.01% 1429
2025
Q4 		$2.72K Buy
+100
New +$3.51K ﹤0.01% 1418

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Triumph Capital Management's AGIO Position: Q2 2026 in Review

Triumph Capital Management held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 100 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Triumph Capital Management first reported a position in AGIO in Q4 2025 and has held it in 3 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Triumph Capital Management held 100 shares of Agios Pharmaceuticals worth $3.71K as of Q2 2026.
  • Triumph Capital Management left its Agios Pharmaceuticals share count unchanged in Q2 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1448 holding.
  • Triumph Capital Management first reported a position in Agios Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.